BioSpace News Archive

Pharmacy Times® also will be working with NPC to build better health care policy research, communicate value of biopharmaceuticals

Certis Oncology Solutions, a precision oncology and translational sciences company, announced it will make available its personalized approach to drug efficacy testing to the commercial pharmaceutical industry.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced that company management will attend the ICR Conference 2021, which is being held virtually from January 11th-14th.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the substantial completion of its strategic business unit and products review which will enable the company to better serve patients and healthcare providers and further expand its leadership in Women’s Health, Oncology and Mental Health.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the 2021 ICR Conference, which takes place January 11-14, 2021.

Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company’s clinical assets and cash resources, which amounted to $47.3 million as of September 30, 2020.

REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on the RGX-314 programs, including the announcement that the pivotal program for RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) is now active.

– Transaction Accelerates Hologic’s Entry into Oncology Growth Market, Provides New Lab Capabilities – – Hologic’s Commercial Resources, Expertise in Molecular Automation Expected to Boost Biotheranostics Growth –

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures announced that it will participate in the H.C. Wainwright Bioconnect 2021 Conference taking place virtually January 11-14, 2021.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at three upcoming virtual conferences.